Serotonergic psychedelics, such as psilocybin and LSD, are also commonly referred to as hallucinogens because at higher "trip-inducing" doses (as opposed to microdoses), these drugs typically trigger ...

Shionogi & Co. Ltd. has synthesized spiroheterocycle derivatives acting as 5-HT2A and 5-HT2C receptor antagonists and/or inverse agonists reported to be useful for the treatment of neurodegeneration.

Delix Therapeutics recently published findings from a study about the mechanism that causes psychoplastogens and serotonin to activate the 5-HT2A receptor in different ways. The paper, developed in ...

Suven Life Sciences Ltd. has identified 5-HT1A receptor agonists and 5-HT2A receptor antagonists reported to be useful for the treatment of depression, insomnia, schizophrenia, bipolar and cognitive ...

A new study provides a detailed look at how the psychedelic compound psilocin acts on specific neurons within the brain. The ...

CSPC Pharmaceutical Group ( ($HK:1093) ) has provided an update. CSPC Pharmaceutical Group Limited has announced that its new chemical drug, ...

This article was originally published on Psychedelic Spotlight and appears here with permission. New study suggests that a non-hallucinogenic LSD analog may hold therapeutic potential for mood ...

STUART, Fla.--(BUSINESS WIRE)--Cognigenics, a pioneering company in RNA-based therapeutics for neuropsychiatric conditions and neurocognitive disorders, announced the publication of its latest ...

Psilocybin-based therapies are nearing FDA review, raising hopes and concerns about safety, scalability, and the therapy’s ...

SEATTLE, WA and IRVINE, CA / ACCESSWIRE / October 5, 2023 / Küleon LLC, a private biotechnology company that has built the industry's largest library of serotonergic drugs exhibiting G protein-biased ...

SAN DIEGO, Calif.--By using positron emission tomography (PET) to study the brain's neuroreceptors in relation to obesity, scientists may be getting closer to determining important information about ...